Studies presented at Obesity Week 2025 validate the test’s ability to predict weight-loss response to GLP-1 drugs like semaglutide, including in diverse patient populations and post-bariatric surgery patients.
In conjunction with Obesity Care Week, a national survey from Phenomix Sciences among medication-experienced patients found that GLP-1 outcomes, tolerability, and downstream care needs vary widely, reinforcing the need for more individualized obesity care.
Findings presented at the 2026 Pacific Symposium on Biocomputing demonstrate feasibility of using genetic and behavioral data to assess Emotional Hunger risk in obesity.
The extensive body of research from Mayo Clinic emphasizes major advancements in obesity, including prediction of GLP-1 side effects, a new obesity sub-phenotype, and insights into personalized bariatric and endoscopic procedures.
Launching at HLTH 2024, the groundbreaking partnership offers payers, health systems, employers, and life science organizations access to personalized obesity care and treatment planning based on a patient’s DNA.
Respondents ages 18 to 65 highlight urgency for medical recognition, scientifically proven interventions, and genetic testing for personalized obesity treatment.
